A Lamin Family-Based Signature Predicts Prognosis and Immunotherapy Response in Hepatocellular Carcinoma

Background. Lamin family members play crucial roles in promoting oncogenesis and cancer development. The values of lamin family in predicting prognosis and immunotherapy response remain largely unclarified. Our research is aimed at comprehensively estimating the clinical significance of lamin family...

Full description

Saved in:
Bibliographic Details
Main Authors: Yongyu Yang, Wang Xiao, Ruoqi Liu, Lei Gao, Junzhang Chen, Heping Kan
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Journal of Immunology Research
Online Access:http://dx.doi.org/10.1155/2022/4983532
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849684503209967616
author Yongyu Yang
Wang Xiao
Ruoqi Liu
Lei Gao
Junzhang Chen
Heping Kan
author_facet Yongyu Yang
Wang Xiao
Ruoqi Liu
Lei Gao
Junzhang Chen
Heping Kan
author_sort Yongyu Yang
collection DOAJ
description Background. Lamin family members play crucial roles in promoting oncogenesis and cancer development. The values of lamin family in predicting prognosis and immunotherapy response remain largely unclarified. Our research is aimed at comprehensively estimating the clinical significance of lamin family in hepatocellular carcinoma and constructing a novel lamin family-based signature to predict prognosis and guide the precise immunotherapy. Methods. The expression features and prognostic value of LMNA, LMNB1, and LMNB2 were explored in the TCGA and GEO databases. The biological functions of LMNB1 and LMNB2 were validated by in vitro assays. A lamin family-based signature was built using the TCGA training set. The TCGA test set, entire TCGA set, and GSE14520 set were used to validate its predictive power. Univariate and multivariate analyses were performed to evaluate the independence of the lamin family-based signature from other clinicopathological characteristics. A nomogram was constructed using the lamin family-based signature and TNM stage. The associations of this signature with molecular pathways, clinical characteristics, immune cell infiltration, and immunotherapy response were analyzed. Results. Lamin family members were upregulated in HCC. Upregulation of LMNB1 and LMNB2 promoted HCC proliferation, migration, and invasion. The predictive signature was initially established based on LMNB1 and LMNB2 which could effectively identify differences in overall survival, immune cell infiltration, and clinicopathological characteristics of high- and low-risk patients. The nomogram showed high prognostic predictive accuracy. Importantly, the lamin family-based signature was correlated with immune suppression and expression of immune checkpoint molecules. Conclusions. The lamin family-based signature is a robust biomarker to predict overall survival and immunotherapy response in HCC. High-risk score patients have a poorer overall survival and might be more sensitive to immunotherapy. This signature may contribute to improving individualized prognosis prediction and precision immunotherapy for HCC patients.
format Article
id doaj-art-c0a1a3b7cdaf41e088bec01a6d175501
institution DOAJ
issn 2314-7156
language English
publishDate 2022-01-01
publisher Wiley
record_format Article
series Journal of Immunology Research
spelling doaj-art-c0a1a3b7cdaf41e088bec01a6d1755012025-08-20T03:23:26ZengWileyJournal of Immunology Research2314-71562022-01-01202210.1155/2022/4983532A Lamin Family-Based Signature Predicts Prognosis and Immunotherapy Response in Hepatocellular CarcinomaYongyu Yang0Wang Xiao1Ruoqi Liu2Lei Gao3Junzhang Chen4Heping Kan5Division of Hepatobiliopancreatic SurgeryDivision of Hepatobiliopancreatic SurgeryDivision of Hepatobiliopancreatic SurgeryDepartment of NeurosurgeryDivision of Hepatobiliopancreatic SurgeryDivision of Hepatobiliopancreatic SurgeryBackground. Lamin family members play crucial roles in promoting oncogenesis and cancer development. The values of lamin family in predicting prognosis and immunotherapy response remain largely unclarified. Our research is aimed at comprehensively estimating the clinical significance of lamin family in hepatocellular carcinoma and constructing a novel lamin family-based signature to predict prognosis and guide the precise immunotherapy. Methods. The expression features and prognostic value of LMNA, LMNB1, and LMNB2 were explored in the TCGA and GEO databases. The biological functions of LMNB1 and LMNB2 were validated by in vitro assays. A lamin family-based signature was built using the TCGA training set. The TCGA test set, entire TCGA set, and GSE14520 set were used to validate its predictive power. Univariate and multivariate analyses were performed to evaluate the independence of the lamin family-based signature from other clinicopathological characteristics. A nomogram was constructed using the lamin family-based signature and TNM stage. The associations of this signature with molecular pathways, clinical characteristics, immune cell infiltration, and immunotherapy response were analyzed. Results. Lamin family members were upregulated in HCC. Upregulation of LMNB1 and LMNB2 promoted HCC proliferation, migration, and invasion. The predictive signature was initially established based on LMNB1 and LMNB2 which could effectively identify differences in overall survival, immune cell infiltration, and clinicopathological characteristics of high- and low-risk patients. The nomogram showed high prognostic predictive accuracy. Importantly, the lamin family-based signature was correlated with immune suppression and expression of immune checkpoint molecules. Conclusions. The lamin family-based signature is a robust biomarker to predict overall survival and immunotherapy response in HCC. High-risk score patients have a poorer overall survival and might be more sensitive to immunotherapy. This signature may contribute to improving individualized prognosis prediction and precision immunotherapy for HCC patients.http://dx.doi.org/10.1155/2022/4983532
spellingShingle Yongyu Yang
Wang Xiao
Ruoqi Liu
Lei Gao
Junzhang Chen
Heping Kan
A Lamin Family-Based Signature Predicts Prognosis and Immunotherapy Response in Hepatocellular Carcinoma
Journal of Immunology Research
title A Lamin Family-Based Signature Predicts Prognosis and Immunotherapy Response in Hepatocellular Carcinoma
title_full A Lamin Family-Based Signature Predicts Prognosis and Immunotherapy Response in Hepatocellular Carcinoma
title_fullStr A Lamin Family-Based Signature Predicts Prognosis and Immunotherapy Response in Hepatocellular Carcinoma
title_full_unstemmed A Lamin Family-Based Signature Predicts Prognosis and Immunotherapy Response in Hepatocellular Carcinoma
title_short A Lamin Family-Based Signature Predicts Prognosis and Immunotherapy Response in Hepatocellular Carcinoma
title_sort lamin family based signature predicts prognosis and immunotherapy response in hepatocellular carcinoma
url http://dx.doi.org/10.1155/2022/4983532
work_keys_str_mv AT yongyuyang alaminfamilybasedsignaturepredictsprognosisandimmunotherapyresponseinhepatocellularcarcinoma
AT wangxiao alaminfamilybasedsignaturepredictsprognosisandimmunotherapyresponseinhepatocellularcarcinoma
AT ruoqiliu alaminfamilybasedsignaturepredictsprognosisandimmunotherapyresponseinhepatocellularcarcinoma
AT leigao alaminfamilybasedsignaturepredictsprognosisandimmunotherapyresponseinhepatocellularcarcinoma
AT junzhangchen alaminfamilybasedsignaturepredictsprognosisandimmunotherapyresponseinhepatocellularcarcinoma
AT hepingkan alaminfamilybasedsignaturepredictsprognosisandimmunotherapyresponseinhepatocellularcarcinoma
AT yongyuyang laminfamilybasedsignaturepredictsprognosisandimmunotherapyresponseinhepatocellularcarcinoma
AT wangxiao laminfamilybasedsignaturepredictsprognosisandimmunotherapyresponseinhepatocellularcarcinoma
AT ruoqiliu laminfamilybasedsignaturepredictsprognosisandimmunotherapyresponseinhepatocellularcarcinoma
AT leigao laminfamilybasedsignaturepredictsprognosisandimmunotherapyresponseinhepatocellularcarcinoma
AT junzhangchen laminfamilybasedsignaturepredictsprognosisandimmunotherapyresponseinhepatocellularcarcinoma
AT hepingkan laminfamilybasedsignaturepredictsprognosisandimmunotherapyresponseinhepatocellularcarcinoma